Imaging of Anal Squamous Cell Carcinoma: Survey Results and Expert Opinion from the Rectal and Anal Cancer Disease-Focused Panel of the Society of Abdominal Radiology

[1]  S. Steigen,et al.  Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[3]  V. Goh,et al.  A Prospective Study of Diffusion-weighted Magnetic Resonance Imaging as an Early Prognostic Biomarker in Chemoradiotherapy in Squamous Cell Carcinomas of the Anus. , 2020, Clinical oncology (Royal College of Radiologists (Great Britain)).

[4]  H. Geinitz,et al.  Additional Value of 2-[18F]FDG PET/CT Comparing to MRI in Treatment Approach of Anal Cancer Patients , 2020, Journal of clinical medicine.

[5]  V. Valentini,et al.  The prognostic role of FDG PET/CT before combined radio-chemotherapy in anal cancer patients , 2019, Annals of Nuclear Medicine.

[6]  V. Goh,et al.  MRI heterogeneity analysis for prediction of recurrence and disease free survival in anal cancer. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  Clarence K. Wong,et al.  Prognostic utility of pre- and post-treatment FDG-PET parameters in anal squamous cell carcinoma. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[8]  E. Malinen,et al.  Anal cancer chemoradiotherapy outcome prediction using 18F-fluorodeoxyglucose positron emission tomography and clinicopathological factors. , 2019, The British journal of radiology.

[9]  G. Treglia,et al.  Prognostic Significance of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography in Anal Squamous Cell Carcinoma: A Systematic Review and a Meta-Analysis , 2018, Contrast media & molecular imaging.

[10]  S. Steele,et al.  The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for Anal Squamous Cell Cancers (Revised 2018). , 2018, Diseases of the colon and rectum.

[11]  David H. Kim,et al.  Use of magnetic resonance imaging in rectal cancer patients: Society of Abdominal Radiology (SAR) rectal cancer disease-focused panel (DFP) recommendations 2017 , 2018, Abdominal Radiology.

[12]  V. Goh,et al.  The impact of MRI sequence on tumour staging and gross tumour volume delineation in squamous cell carcinoma of the anal canal , 2017, European Radiology.

[13]  D. Jonker,et al.  PET imaging in anal canal cancer: a systematic review and meta-analysis. , 2017, The British journal of radiology.

[14]  Stuart A. Taylor,et al.  Magnetic resonance imaging for clinical management of rectal cancer: Updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting , 2017, European Radiology.

[15]  M. Zwahlen,et al.  Nodal stage migration and prognosis in anal cancer: a systematic review, meta-regression, and simulation study. , 2017, The Lancet. Oncology.

[16]  T. Hellebust,et al.  Target volume delineation of anal cancer based on magnetic resonance imaging or positron emission tomography , 2017, Radiation oncology.

[17]  T. Hellebust,et al.  Target volume delineation of anal cancer based on magnetic resonance imaging or positron emission tomography , 2017, Radiation Oncology.

[18]  V. Goh,et al.  Association of Coloproctology of Great Britain & Ireland (ACPGBI): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) – Anal Cancer , 2017, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[19]  J. Hartley,et al.  Association of Coloproctology of Great Britain & Ireland (ACPGBI): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) – Follow Up, Lifestyle and Survivorship , 2017, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[20]  P. Tekkis,et al.  Discrepancies between NCCN and ESMO guidelines in the management of anal cancer: a qualitative review , 2017, Updates in Surgery.

[21]  M. Ducreux,et al.  Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP). , 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[22]  V. Goh,et al.  Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[23]  L. Giovanella,et al.  Diagnostic Performance of Positron Emission Tomography/Computed Tomography Using Fluorine-18 Fluorodeoxyglucose in Detecting Locoregional Nodal Involvement in Patients with Anal Canal Cancer: A Systematic Review and Meta-Analysis , 2014, TheScientificWorldJournal.

[24]  V. Goh,et al.  MRI of anal cancer: assessing response to definitive chemoradiotherapy , 2014, Abdominal Imaging.

[25]  J. Ledermann,et al.  Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. , 2013, The Lancet. Oncology.

[26]  V. Goh,et al.  Magnetic resonance imaging assessment of squamous cell carcinoma of the anal canal before and after chemoradiation: can MRI predict for eventual clinical outcome? , 2010, International journal of radiation oncology, biology, physics.

[27]  P. Grigsby,et al.  Anal cancer maximum F-18 fluorodeoxyglucose uptake on positron emission tomography is correlated with prognosis. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[28]  J. Northover,et al.  Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  A. Hogg,et al.  The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer , 2009, British Journal of Cancer.

[30]  B. O'neill,et al.  Pelvic phased-array MR imaging of anal carcinoma before and after chemoradiation. , 2008, The British journal of radiology.

[31]  B. Carrington,et al.  Magnetic resonance imaging of anal cancer. , 2005, Clinical radiology.

[32]  D. Tarantino,et al.  Endoanal Ultrasound in the Staging and Management of Squamous-Cell Carcinoma of the Anal Canal , 2002, Diseases of the colon and rectum.

[33]  U. Herzog,et al.  Endoanal ultrasonography in the follow-up of anal carcinoma , 1994, Surgical Endoscopy.

[34]  V. Vaitkevicius,et al.  Combined therapy for cancer of the anal canal: A preliminary report , 1974, Diseases of the colon and rectum.

[35]  C. Perotti,et al.  Anal cancer FDG-PET standard uptake value: correlation with tumor characteristics, treatment response and survival , 2015, La radiologia medica.

[36]  Hodgkin Lymphoma.  NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines , 2014 .